Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).

Published on May 25, 2020in Journal of Clinical Oncology44.544
路 DOI :10.1200/JCO.2020.38.15_SUPPL.8536
Sagar Lonial102
Estimated H-index: 102
(Emory University Hospital),
Hans C. Lee16
Estimated H-index: 16
(University of Texas MD Anderson Cancer Center)
+ 17 AuthorsAdam D. Cohen47
Estimated H-index: 47
(UPenn: University of Pennsylvania)
Sources
Abstract
8536Background: Single-agent belantamab mafodotin (B-cell maturation antigen targeting immunoconjugate) showed clinically meaningful activity and manageable safety in patients with heavily pre-trea...
馃摉 Papers frequently viewed together
38 Authors (Al-Ola Abdallah)
17 Authors (Suzanne Trudel, ..., Adam D. Cohen)
References0
Newest
Cited By19
Newest
#1Geraldine Ferron-Brady (GSK: GlaxoSmithKline)H-Index: 9
#2Chetan Rathi (GSK: GlaxoSmithKline)H-Index: 8
Last. Roxanne C. Jewell (RTP: Research Triangle Park)H-Index: 13
view all 7 authors...
Belantamab mafodotin is an antibody-drug conjugate comprising a humanized anti-B-cell maturation antigen (BCMA) monoclonal antibody conjugated to monomethyl auristatin F (MMAF) via a protease-resistant maleimidocaproyl linker. Single-agent belantamab mafodotin showed clinically meaningful activity and manageable safety in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM) in the phase I DREAMM-1 and phase II DREAMM-2 studies and is approved by the US Food and Drug Admin...
Source
#1Arjun Lakshman (Mayo Clinic)H-Index: 12
#2Shaji Kumar (Mayo Clinic)H-Index: 128
Patients with multiple myeloma who are refractory to currently available effective therapies have short expected survival. Modalities harvesting the knowledge of the immune characteristics and microenvironment of myeloma such as chimeric antigen receptor (CAR) T-lymphocytes, bispecific antibodies and antibody-drug conjugates have shown potential in early phase trials. Based on data from phase 2 studies, idecabtagene vicleucel (ide cel), an anti-BCMA CAR T-product and belantamab mafodotin (belama...
Source
#2Martin SchrederH-Index: 19
Last. Peter Neumeister (Medical University of Graz)H-Index: 24
view all 11 authors...
Since the introduction of first-generation proteasome inhibitors and immunomodulatory agents, the multiple myeloma (MM) treatment landscape has undergone a remarkable development. Most recently, immunotherapeutic strategies targeting the B cell maturation antigen (BCMA) entered the clinical stage providing access to highly anticipated novel treatment strategies. At present, numerous different approaches investigate BCMA as an effective multi-modal target. Currently, BCMA-directed antibody鈥揹rug c...
Source
#1Martina Kleber (University of Basel)H-Index: 1
Last. Evangelos TerposH-Index: 87
view all 3 authors...
Despite the discoveries of numerous agents including next generation proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, multiple myeloma (MM) remains an incurable disease. The field of myeloma treatment in refractory or relapsed patients after standard therapy entered a new era due to the B-cell maturation antigen (BMCA) targeted approach. BCMA is a member of the tumor necrosis factor receptor family with high expression in mature B-lymphocytes and plasma cells. Given the ...
Source
#1Carlyn Tan (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 5
#2Urvi A Shah (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 11
PURPOSE OF REVIEW Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a significant number of patients still progress on current available therapies. Here, we review treatment modalities used to target BCMA in the treatment of MM, specifically antibody-drug conjugates (ADC), bispecific antibody constructs, and chimeric antibody receptor (CAR) modified T-cell therapies. We will provide an overview of therapies from these classes that have presented or publi...
Source
#1Nisha Joseph (Emory University)H-Index: 9
#2Yu-Tzu Tai (Harvard University)H-Index: 89
Last. Sagar Lonial (Emory University)H-Index: 102
view all 0 authors...
Though survival outcomes in multiple myeloma patients have improved drastically over the past few decades, there still remains an ongoing need for effective and tolerable treatment options in the relapsed and refractory space. Encouragingly, there have been three recent FDA approvals for triple-class refractory multiple myeloma, and there is promising ongoing development of additional agents with varying novel mechanisms of action. Here, we will review the most recent data on both belantamab maf...
Source
#7Al-Ola Abdallah (KU: University of Kansas)H-Index: 9
Background null On the basis of the DREAMM-2 study (ClinicalTrials.gov identifier NCT03525678), single-agent belantamab mafodotin (belamaf) was approved for patients with relapsed or refractory multiple myeloma (RRMM) who received 鈮4 prior therapies, including anti-CD38 therapy. The authors investigated longer term efficacy and safety outcomes in DREAMM-2 after 13 months of follow-up among patients who received belamaf 2.5 mg/kg. null Methods null DREAMM-2 is an ongoing, phase 2, open-label, 2-a...
Source
#1Joshua Richter (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 10
#2Santiago Thibaud (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 6
Abstract The last decade has seen a marked improvement in the outcomes of patients with multiple myeloma. Much of this has been due to not only the advent of new therapies, but their inherent ability to be combined into 3 and 4 drug regimens without resulting in unacceptable toxicity. The general gestalt has been to combine agents of varied mechanisms of action. With the primary classes of agents such as proteasome inhibitors and immunomodulatory drugs as bases, the advent of antibody-based ther...
Source
Patients with relapsed and refractory multiple myeloma (RRMM) who are triple-class exposed (to an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody) have limited treatment options and there is no standard of care. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, demonstrated efficacy in triple-class exposed RRMM patients in the KarMMa trial (NCT03361748). In this retrospective study (KarMMa-RW), patient-level data from triple-class exposed RRMM pat...
Source
#1Sagar Lonial (Emory University)H-Index: 102
#2Ajay K. Nooka (Emory University)H-Index: 33
Last. Andrzej Jakubowiak (U of C: University of Chicago)H-Index: 59
view all 20 authors...
Belantamab mafodotin (belamaf) demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM) in DREAMM-2 (NCT03525678). Corneal events, specifically keratopathy (including superficial punctate keratopathy and/or microcyst-like epithelial changes (MECs), eye examination findings with/without symptoms), were common, consistent with reports from other antibody-drug conjugates. Given the novel nature of corneal events in RRMM management, g...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.